Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  malignant extragonadal non-seminomatous germ cell tumor
Stage/Subtype:  malignant extragonadal non-seminomatous germ cell tumor
Country:  U.S.A.
Trial Type:  Treatment
Results 1-10 of 10 for your search:
Start Over
Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients with Relapsed or Refractory Germ Cell Tumors
Phase: Phase III
Type: Treatment
Age: 14 and over
Trial IDs: A031102, NCI-2014-01696, PA031102_A01PAMDREVW01, NCT02375204
Vaccine Therapy and Iscomatrix with or without Cyclophosphamide and Celecoxib in Treating Patients with Thoracic Malignancies or Tumors That Have Spread to the Chest Cavity
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 14-C-0053, NCI-2014-02465, 140053, P131392, NCT02054104
Gemcitabine Hydrochloride, Oxaliplatin, and Paclitaxel in Treating Patients With Refractory Germ Cell Cancer
Phase: Phase II
Type: Treatment
Age: 16 and over
Trial IDs: 4T-03-1, NCI-2011-01350, NCT00183820
Autologous Peripheral Blood Stem Cell Transplant for Germ Cell Tumors
Phase: Phase II
Type: Treatment
Age: 10 to 69
Trial IDs: MT2005-21, NCI-2010-01700, 2006LS032, UMN-2006LS032, UMN-MT2005-21, UMN-0608M90586, NCT00432094
High-Dose Chemotherapy, Bevacizumab and Stem Cell Transplant in Treating Patients with Recurrent Germ Cell Tumors
Phase: Phase II
Type: Treatment
Age: 12 to 65
Trial IDs: 2008-0378, NCI-2011-01631, NCT00936936
PD 0332991 in Treating Patients With Refractory Solid Tumors
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: UPCC 03909, NCI-2009-01467, NCT01037790
Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 117019, NCI-2014-00802, NCT02034110
Simvastatin, Topotecan Hydrochloride, and Cyclophosphamide in Treating Younger Patients with Relapsed and/or Refractory Solid and CNS Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 to 29
Trial IDs: AFLACST1402, NCI-2015-00420, IRB00078790, NCT02390843
Start Over